Pharmaceuticals News and Research

RSS

Study: Chronic mitral valve disease similar in humans and dogs

For more than 15 years, Kansas State University researcher Michele Borgarelli has studied heart diseases in man's best friend.

4 Aug 2011

Pharming, Santarus reach SPA agreement with FDA for RHUCIN Phase III trial

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.

4 Aug 2011

Accurate, non-invasive and inexpensive test can detect Alzheimer's

Scientists from Durin Technologies, Inc., and the University of Medicine and Dentistry of New Jersey (UMDNJ)-School of Osteopathic Medicine have developed a blood test that uses human protein microarrays to detect the presence of specific antibodies in the blood that can be used to diagnose Alzheimer's disease with unprecedented accuracy.

4 Aug 2011

ICORE Healthcare receives URAC Accreditation for Specialty Pharmacy

Magellan Health Services Inc. has announced that ICORE Healthcare, its Specialty Pharmaceutical division, has been awarded the Specialty Pharmacy Accreditation from URAC, a Washington, D.C. based health care accrediting organization that establishes quality standards for the health care industry.

4 Aug 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

Par Pharmaceutical reports second quarter total revenues of $224.2 million

Par Pharmaceutical Companies, Inc. today reported results for the second quarter ended June 30, 2011.

3 Aug 2011

Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation today announced that the companies have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia.

3 Aug 2011

SuperGen second quarter net income decreases to $903,000

SuperGen, Inc. today reported financial results for the second quarter ended June 30, 2011. The Company reported net income for the 2011 second quarter of $903,000, or $0.01 per basic and diluted share, compared with $961,000, or $0.02 per basic and diluted share, for the same prior year period.

3 Aug 2011

Zalicus second quarter revenue decreases to $1.8 million

Zalicus Inc. today reported financial results for the second quarter ended June 30, 2011.

3 Aug 2011

BioClinica second quarter service revenues increase 8.7% to $16.9 million

BioClinica Inc., a global provider of clinical trial management solutions, today announced its financial results for the second quarter and six months ended June 30, 2011.

From Clario 3 Aug 2011

New approach to overcome complexities of developing more effective drugs for treating diseases

Pharmaceutical scientists typically face a meager five percent success rate for anti-cancer drugs in clinical trials. To help improve this success rate, Japanese scientists, led by Dr. Tetsuya Terasaki, one of the top pharmaceutical scientists focused on drug transporters, have developed a new approach designed to overcome complexities of developing new, more effective drugs to treat diseases, including cancer.

3 Aug 2011

Role of molecular imaging in diagnosis and clinical trials

Two new studies published in the August issue of The Journal of Nuclear Medicine (JNM) provide insight into the potential of positron emission tomography (PET) to differentiate between types of dementia and to identify pharmaceuticals to slow the progress of dementia. With proposed National Institute on Aging (NIA) and the Alzheimer's Association guidelines for detecting Alzheimer's-related brain changes expected in September, these articles give a preview of what may be to come.

3 Aug 2011

Biotica acquires full rights to rapamycin analogue program from Pfizer

Biotica Technology Ltd. today announced that it has regained full rights from Pfizer Inc. to its rapamycin analogue program, including transfer of data and materials.

3 Aug 2011

Memantine drug could boost cognitive function in people with Down syndrome

A University of Colorado School of Medicine scientist is completing a major clinical trial on a drug that could boost cognitive function in those with Down syndrome, significantly improving their quality of life and representing a potential milestone in research on this genetic condition.

3 Aug 2011

MSMB offers $18 per share for Amag acquisition

MSMB Capital Management today announced that it has made a proposal to the Board of Directors of Amag Pharmaceuticals Inc. to acquire all of the outstanding shares of common stock of Amag for $18 per share in cash or an aggregate of $378 million.

3 Aug 2011

Akorn enters agreement to acquire minority ownership in Aciex

Akorn, Inc., a niche specialty pharmaceutical company, today announced that it has entered into an agreement to acquire a minority ownership in Westborough, MA, based Aciex Therapeutics Inc., an ophthalmic drug development company with a focus on developing novel therapeutics to treat ocular diseases.

3 Aug 2011

Needle-free nanopatch vaccine delivery system

The needle-free nanopatch vaccine delivery system is coming soon after a consortium of investors put up $15 million for its development. The money will enable University of Queensland's Professor Mark Kendall to continue his work on the technology. It is described as the biggest breakthrough in vaccine delivery since the invention of the syringe more than 150 years ago.

3 Aug 2011

GSK, NPS enter agreement to evaluate ronacaleret in new indications

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported that it has entered into a new agreement with GlaxoSmithKline (GSK), that terminates and replaces a prior collaborative research and license agreement between NPS and GSK from 1993, which focused on the discovery and development of small molecule antagonists of the calcium receptor that increase secretion of parathyroid hormone.

3 Aug 2011

BioSante closes underwritten public offering of common stock

BioSante Pharmaceuticals, Inc. today announced the closing of its underwritten public offering of 16.0 million shares of common stock at a public offering price of $3.00 per share, for total gross proceeds of $48.0 million before underwriting discounts and commissions.

3 Aug 2011

Pfizer second-quarter revenues decrease 1% to $17.0 billion

Pfizer Inc. today reported financial results for second-quarter 2011. As a result of Pfizer's decision to sell the Capsugel business, all revenues and expenses related to Capsugel in all periods presented are reflected in a single line, Discontinued operations - net of tax.

3 Aug 2011